Christian Teschendorf

Summary

Country: Germany

Publications

  1. ncbi A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
  2. ncbi Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma
    Christian Teschendorf
    Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Anticancer Res 26:311-7. 2006
  3. ncbi Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells
    Christian Teschendorf
    Department of Internal Medicine, Knappschaftskrankenhaus, University of Bochum, 44892 Bochum, Germany
    Anticancer Res 30:1931-5. 2010
  4. ncbi Gene therapy delivery of endostatin enhances the treatment efficacy of radiation
    Wenyin Shi
    Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, FL 32610, USA
    Radiother Oncol 66:1-9. 2003
  5. ncbi Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus
    Christian Teschendorf
    Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, P O Box 100266, JHMHSC, Gainesville, FL 32610, USA
    Anticancer Res 22:3325-30. 2002
  6. ncbi Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo
    Wenyin Shi
    Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, Florida 32610, USA
    Cancer Gene Ther 9:513-21. 2002

Collaborators

  • Dietmar Siemann
  • Wenyin Shi
  • Clemens Giessen
  • Sebastian Stintzing
  • Jens Freiberg-Richter
  • Markus Bangerter
  • Ludwig Fischer von Weikersthal
  • Dominik Paul Modest
  • Frank Kullmann
  • Philipp Aubele
  • Nicolas Moosmann
  • Julia Mayerle
  • Markus Sieber
  • Ursula Vehling-Kaiser
  • Christoph Schulz
  • Axel Hinke
  • Volker Heinemann
  • Claudio Denzlinger

Detail Information

Publications6

  1. ncbi A randomized, phase III trial of capecitabine plus bevacizumab (Cape-Bev) versus capecitabine plus irinotecan plus bevacizumab (CAPIRI-Bev) in first-line treatment of metastatic colorectal cancer: the AIO KRK 0110 trial/ML22011 trial
    Clemens Giessen
    Department of Medical Oncology, Klinikum Grosshadern, University of Munich, Germany
    BMC Cancer 11:367. 2011
    ..The present study investigates the question whether this statement holds true also for bevacizumab-based first-line treatment including escalation- and de-escalation strategies...
  2. ncbi Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinoma
    Christian Teschendorf
    Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA
    Anticancer Res 26:311-7. 2006
    ..Materials and Methods: The transduction efficiency of rAAV2 in pancreatic and colon cancer was compared to that of recombinant adenovirus (rAd) in vitro and in vivo using green fluorescent protein (GFP)...
  3. ncbi Efficacy of recombinant adeno-associated viral vectors serotypes 1, 2, and 5 for the transduction of pancreatic and colon carcinoma cells
    Christian Teschendorf
    Department of Internal Medicine, Knappschaftskrankenhaus, University of Bochum, 44892 Bochum, Germany
    Anticancer Res 30:1931-5. 2010
    ..The development of efficient and specific vector systems remains a central issue in gene therapy. Several different adeno-associated virus (AAV) serotypes have so far been characterized so far which show different tissue tropisms...
  4. ncbi Gene therapy delivery of endostatin enhances the treatment efficacy of radiation
    Wenyin Shi
    Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, FL 32610, USA
    Radiother Oncol 66:1-9. 2003
    ..05). CONCLUSION: The delivery of endostatin via rAAV vectors may provide an effective means of enhancing the anti-tumor efficacy of radiation therapy...
  5. ncbi Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus
    Christian Teschendorf
    Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, P O Box 100266, JHMHSC, Gainesville, FL 32610, USA
    Anticancer Res 22:3325-30. 2002
    ..Silencing of the viral CMV immediate early enhancer promoter can be a problem in certain cell types when engineering stable cell lines...
  6. ncbi Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivo
    Wenyin Shi
    Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, Florida 32610, USA
    Cancer Gene Ther 9:513-21. 2002
    ..This endostatin level was sufficient to inhibit tumor cell-induced angiogenesis and to suppress both the initiation and subsequent growth of a human colorectal cancer model...